Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tapentadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tapentadol SCHEMBL29447436 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL3841350 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL146800 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL1425181 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL116924 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL16267561 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL16266162 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL416917 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL16267909 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A | |
| Tapentadol SCHEMBL29611116 | 1.00 | OPRM1 (1.00) | OPRM1SLC22A1ADRA1AADRB1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007156-B2 | Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol | GRUENENTHAL GMBH (DE) | 2021-05-18 | — | — | US | claimed |
| US-10813890-B2 | Pharmaceutical combination | Grünenthal GmbH (DE) | 2020-10-27 | — | — | US | claimed |
| US-20190133971-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2019-05-09 | — | — | US | claimed |
| EP-3139906-B1 | A SLOW-RELEASE PHARMACEUTICAL FORMULATION | G L PHARMA GMBH (AT) | 2019-04-10 | — | — | EP | claimed |
| US-10206890-B2 | Pharmaceutical combination | GRUENENTHAL GMBH (DE) | 2019-02-19 | — | — | US | claimed |
| US-20180221308-A1 | PROLONGED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)PHENOL | GRUENENTHAL GMBH (DE) | 2018-08-09 | — | — | US | claimed |
| EP-3300726-A1 | INTRATHECAL OR EPIDURAL ADMINISTRATION OF 3-[(1S,2S)-3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL]PHENOL | Grünenthal GmbH (DE) | 2018-04-04 | — | — | EP | claimed |
| EP-3287447-A1 | SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL | Grünenthal GmbH (DE) | 2018-02-28 | — | — | EP | claimed |
| EP-2736501-B1 | INTRATHECAL OR EPIDURAL ADMINISTRATION OF 3-[(1S,2S)-3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL]PHENOL | GRUENENTHAL GMBH (DE) | 2017-12-20 | — | — | EP | claimed |
| US-20170333369-A1 | Pharmaceutical Combination | GRUENENTHAL GMBH (DE) | 2017-11-23 | — | — | US | claimed |
| JP-2004527491-A | — | — | 2004-09-09 | — | — | JP | claimed |
| EP-1439829-A1 | PHARMACEUTICAL CONTAINING 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)PHENOL AND PROVIDING DELAYED RELEASE OF THE ACTIVE INGREDIENT | Grünenthal GmbH (DE) | 2004-07-28 | — | — | EP | claimed |
| EP-1429754-A1 | COMBINATION OF SELECTED OPIOIDS WITH MUSCARINE ANTAGONISTS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2004-06-23 | — | — | EP | claimed |
| EP-1390023-A2 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2004-02-25 | — | — | EP | claimed |
| WO-2003053427-A1 | USE OF (+)-(1S,2S)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)PHENOL AS ANTI-EMETIC AGENT | Grünenthal GmbH (DE) | 2003-07-03 | — | — | WO | claimed |
| WO-2003035054-A1 | PHARMACEUTICAL CONTAINING 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)PHENOL AND PROVIDING DELAYED RELEASE OF THE ACTIVE INGREDIENT | Grünenthal GmbH (DE) | 2003-05-01 | — | — | WO | claimed |
| WO-2003035053-A1 | PHARMACEUTICAL CONTAINING 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)PHENOL AND PROVIDING DELAYED RELEASE OF THE ACTIVE INGREDIENT | Grünenthal GmbH (DE) | 2003-05-01 | — | — | WO | claimed |
| WO-2003024444-A1 | COMBINATION OF SELECTED OPIOIDS WITH MUSCARINE ANTAGONISTS FOR TREATING URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2003-03-27 | — | — | WO | claimed |
| WO-2002067916-A2 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2002-09-06 | — | — | WO | claimed |
| WO-2002067651-A2 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2002-09-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206890-B2 | Pharmaceutical combination | PYGB, ACHE, OPRM1 | OPRM1 3/4885SLC6A2 667/4885SLC22A1 3627/4885 |
| US-20190133971-A1 | Pharmaceutical Combination | PYGB, ACHE, OPRM1 | OPRM1 3/4885SLC6A2 616/4885SLC22A1 3549/4885 |
| US-10813890-B2 | Pharmaceutical combination | GRIN3A, GRIN2B, GRIN2C | OPRM1 9/4885SLC6A2 629/4885SLC22A1 3310/4885 |
| US-20170333369-A1 | Pharmaceutical Combination | GRIN3A, GRIN2B, GRIN2C | OPRM1 9/4885SLC6A2 629/4885SLC22A1 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.